Author

B. R. Daley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. J. Linke· 2 shared N. E. Sealover· 2 shared P. L. Theard· 2 shared R. L. Kortum· 2 shared J. M. Hughes· 1 shared J. Yang· 1 shared K. Cox· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

7 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. J. Linke

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivJan 27, 2023

In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies

N. E. Sealover, P. L. Theard, J. M. Hughes…·R. L. Kortum

This paper introduces an in situ resistance assay to model acquired resistance to RTK/RAS pathway targeted therapies and shows SHP2 inhibitors can delay resistance development.

DOI 10.1016/j.isci.2023.108711

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivJan 20, 2023

SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis

P. L. Theard, A. J. Linke, N. E. Sealover…·R. L. Kortum

This study shows SOS2 modulates EGFR-PI3K signaling threshold, affecting osimertinib efficacy and resistance in lung adenocarcinoma.

DOI 10.1002/1878-0261.13564

humanexperimental assay

𝕏 PostBluesky